EA201992762A1 - Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли - Google Patents

Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли

Info

Publication number
EA201992762A1
EA201992762A1 EA201992762A EA201992762A EA201992762A1 EA 201992762 A1 EA201992762 A1 EA 201992762A1 EA 201992762 A EA201992762 A EA 201992762A EA 201992762 A EA201992762 A EA 201992762A EA 201992762 A1 EA201992762 A1 EA 201992762A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chronic pain
medicines
relief
delivery
transmucosal devices
Prior art date
Application number
EA201992762A
Other languages
English (en)
Inventor
Эндрю Финн
Нирадж Васишт
Original Assignee
Байоделивери Сайенсиз Интернэшнл, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоделивери Сайенсиз Интернэшнл, Инк. filed Critical Байоделивери Сайенсиз Интернэшнл, Инк.
Publication of EA201992762A1 publication Critical patent/EA201992762A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем документе предложены способы лечения хронической боли путем введения низких доз бупренорфина два раза в сутки (или один раз в сутки) с помощью трансмукозального устройства для доставки лекарств. Указанные способы и устройства обеспечивают эффективное лечение хронической боли без значительных побочных эффектов.
EA201992762A 2011-12-21 2012-12-21 Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли EA201992762A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21

Publications (1)

Publication Number Publication Date
EA201992762A1 true EA201992762A1 (ru) 2020-07-31

Family

ID=48669710

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992762A EA201992762A1 (ru) 2011-12-21 2012-12-21 Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли
EA201491046A EA034529B1 (ru) 2011-12-21 2012-12-21 Способ лечения хронической боли у субъекта, принимавшего опиоиды, с применением трансмукозального устройства для доставки лекарств

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201491046A EA034529B1 (ru) 2011-12-21 2012-12-21 Способ лечения хронической боли у субъекта, принимавшего опиоиды, с применением трансмукозального устройства для доставки лекарств

Country Status (16)

Country Link
EP (1) EP2793870A4 (ru)
JP (1) JP6255349B2 (ru)
KR (4) KR20190110628A (ru)
CN (2) CN110123792A (ru)
AU (4) AU2012358308A1 (ru)
BR (1) BR112014015329A8 (ru)
CA (1) CA2859859A1 (ru)
EA (2) EA201992762A1 (ru)
HK (1) HK1203365A1 (ru)
IL (2) IL233075A0 (ru)
IN (1) IN2014DN06117A (ru)
MX (2) MX362217B (ru)
SG (3) SG11201403075XA (ru)
UA (1) UA118540C2 (ru)
WO (1) WO2013096811A2 (ru)
ZA (1) ZA201804381B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
WO2002088157A1 (fr) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
CA2629046C (en) 2005-12-13 2014-04-08 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
KR20090007418A (ko) 2006-04-12 2009-01-16 스피날모우션, 인코포레이티드 후방 척추 장치 및 방법
KR101329496B1 (ko) * 2006-07-21 2013-11-13 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN105833420A (zh) * 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
CN104125828A (zh) 2014-10-29
MX2014007350A (es) 2014-09-15
AU2019202602A1 (en) 2019-05-02
AU2017258916A1 (en) 2017-11-30
CA2859859A1 (en) 2013-06-27
BR112014015329A2 (pt) 2017-06-13
MX2021012154A (es) 2021-11-03
EP2793870A2 (en) 2014-10-29
AU2017258916B2 (en) 2019-01-17
UA118540C2 (uk) 2019-02-11
WO2013096811A3 (en) 2014-07-24
JP2015500886A (ja) 2015-01-08
KR20220047889A (ko) 2022-04-19
EA034529B1 (ru) 2020-02-18
KR20140106720A (ko) 2014-09-03
ZA201804381B (en) 2022-12-21
KR20190110628A (ko) 2019-09-30
IN2014DN06117A (ru) 2015-08-14
WO2013096811A2 (en) 2013-06-27
KR20210003313A (ko) 2021-01-11
EP2793870A4 (en) 2016-02-17
AU2012358308A1 (en) 2014-07-24
AU2021202042A1 (en) 2021-04-29
IL233075A0 (en) 2014-07-31
SG11201403075XA (en) 2014-07-30
EA201491046A1 (ru) 2014-11-28
IL285091A (en) 2021-08-31
MX362217B (es) 2019-01-09
CN110123792A (zh) 2019-08-16
KR102026321B1 (ko) 2019-09-27
SG10201710667YA (en) 2018-02-27
SG10202012743WA (en) 2021-01-28
HK1203365A1 (en) 2015-10-30
JP6255349B2 (ja) 2017-12-27
BR112014015329A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
IN2015DN00450A (ru)
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
TW201642906A (en) Fixed dose combination for pain relief without edema
EA201992762A1 (ru) Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли
EA201791038A1 (ru) Лечение непереносимости энтерального питания
RU2012103957A (ru) Способ лечения и профилактики назальной обструкции у больных полипозным риносинуситом
RU2011120773A (ru) Способ лечения вторичной лактазной недостаточности
BRPI1101656A2 (pt) composições farmacêuticas contento 11, 12- pirazolminociclina e uso no tratamento de dor neuropática
RU2010136364A (ru) Способ лечения алкогольной, никотиновой, наркотической и иных форм зависимостей